Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents

Gadolinium(III) complexes have been widely utilised as magnetic resonance imaging (MRI) contrast agents for decades. In recent years however, concerns have developed about their toxicity, believed to derive from demetallation of the complexes in vivo, and the relatively large quantities of compound...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2019-03, Vol.10 (1), p.1420-1420, Article 1420
Main Authors: Clough, Thomas J., Jiang, Lijun, Wong, Ka-Leung, Long, Nicholas J.
Format: Article
Language:English
Subjects:
639/301/357/997
639/638/11/876
639/638/263/49
639/638/911
Biocompatibility
Contrast agents
Contrast Media - chemistry
Gadolinium
Gadolinium - chemistry
Humanities and Social Sciences
Ligands
Macrocyclic Compounds - chemistry
Magnetic Resonance Imaging
multidisciplinary
NMR
Nuclear magnetic resonance
Resonance
Review
Review Article
Science
Science (multidisciplinary)
Stability
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gadolinium(III) complexes have been widely utilised as magnetic resonance imaging (MRI) contrast agents for decades. In recent years however, concerns have developed about their toxicity, believed to derive from demetallation of the complexes in vivo, and the relatively large quantities of compound required for a successful scan. Recent efforts have sought to enhance the relaxivity of trivalent gadolinium complexes without sacrificing their stability. This review aims to examine the strategic design of ligands synthesised for this purpose, provide an overview of recent successes in gadolinium-based contrast agent development and assess the requirements for clinical translation. Gadolinium(III) complexes are strong enhancers of magnetic resonance imaging (MRI) signals, thus are widely used as contrast agents despite their potential toxicity. Here, the authors review ligand design approaches aimed at improving the stability of Gd(III)-based MRI contrast agents.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-019-09342-3